Multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Control group: Received 30 µg interferon beta-1a
intra-muscular injection
for 6-months. Intervention 2: Intervention group: Received 30 µg interferon beta-1a with 40 mg atorvastatin
for 6-months.
Treatment - Drugs
Control group: Received 30 µg interferon beta-1a
for 6-months
Intervention group: Received 30 µg interferon beta-1a with 40 mg atorvastatin
Sponsors
Vice Chancellor for Research, Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Relapsing-remitting MS patients; at least 1 relapse in the previous 12 months; more than three lesions on spinal or brain magnetic resonance imaging or both; baseline expanded disability status scale (EDSS) from 0 to 3.5; aged 18–60 years. Exclusion criteria: clinical CIS syndrome, progressive MS, MS patients with acute clinical relapses occurring during the study, drug abuse, renal failure, pregnancy, hepatitis diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assay of cell amplification of peripheral blood luokocytes. Timepoint: 6 months after entering the intervention. Method of measurement: MTT assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of cytokines. Timepoint: 6 months after entering the intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFardin Faraji
Arak University of Medical Sciences
Outcome results
None listed